- Molecular NameStavudine
- Synonym2',3'-Didehydro-3'-deoxythimidine; 3'-Deoxy-2'-thymidinene; Estavudina [INN-Spanish]; Sanilvudine; stavudine; Stavudine [Usan:Ban:Inn]; Stavudinum [INN-Latin]; STV
- Weight223.232
- Drugbank_IDDB00649
- ACS_NO3056-17-5
- Show 2D model
- LogP (experiment)-0.81
- LogP (predicted, AB/LogP v2.0)-1.01
- pkaN/A
- LogD (pH=7, predicted)-1.01
- Solubility (experiment)83.3 mg/ml
- LogS (predicted, ACD/Labs)(ph=7)-1.35
- LogSw (predicted, AB/LogsW2.0)8.13
- Sw (mg/ml) (predicted, ACD/Labs)9.86
- No.of HBond Donors3
- No.of HBond Acceptors6
- No.of Rotatable Bonds2
- TPSA88.15
- StatusFDA approved
- AdministrationN/A
- PharmacologyA nucleoside analog reverse transcriptase inhibitor (NARTI) active against HIV.
- Absorption_value100.0
- Absorption (description)The oral absorption rate of stavudine is over 80%.
- Caco_2N/A
- Bioavailability82.0
- Protein binding5.0
- Volume of distribution (VD)0.95 L/kg
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmPhosphorylated intracellularly to stavudine triphosphate, the active substrate for HIV-reverse transcriptase.
- Half lifeElimination, 1.0 to 1.5 h (single dose); intracellular stavudine triphosphate, 3.5 h (measured in vitro); 0.82 to 1.24 h (children).
- ExcretionRenal elimination (ca.40%)
- Urinary ExcretionN/A
- CleranceN/A
- ToxicitySide effects include peripheral neuropathy tingling, burning, numbness, or pain in the hands or feet), fatal lactic acidosis has been reported in patients treated with stavudine (ZERIT) in combination with other antiretroviral agents, severe liver enlargement, inflammation (pain and swelling) of the liver, and liver failure.
- LD50 (rat)N/A
- LD50 (mouse)N/A